Literature DB >> 29243000

RNA interference-based therapy and its delivery systems.

Xiuhui Chen1,2, Lingegowda S Mangala1,3, Cristian Rodriguez-Aguayo3,4, Xianchao Kong2, Gabriel Lopez-Berestein3,4, Anil K Sood5,6,7.   

Abstract

RNA interference (RNAi) is considered a highly specific approach for gene silencing and holds tremendous potential for treatment of various pathologic conditions such as cardiovascular diseases, viral infections, and cancer. Although gene silencing approaches such as RNAi are widely used in preclinical models, the clinical application of RNAi is challenging primarily because of the difficulty in achieving successful systemic delivery. Effective delivery systems are essential to enable the full therapeutic potential of RNAi. An ideal nanocarrier not only addresses the challenges of delivering naked siRNA/miRNA, including its chemically unstable features, extracellular and intracellular barriers, and innate immune stimulation, but also offers "smart" targeted delivery. Over the past decade, great efforts have been undertaken to develop RNAi delivery systems that overcome these obstacles. This review presents an update on current progress in the therapeutic application of RNAi with a focus on cancer therapy and strategies for optimizing delivery systems, such as lipid-based nanoparticles.

Entities:  

Keywords:  Cancer therapy; Delivery systems; Nanoparticles; RNA interference

Mesh:

Substances:

Year:  2018        PMID: 29243000      PMCID: PMC5898634          DOI: 10.1007/s10555-017-9717-6

Source DB:  PubMed          Journal:  Cancer Metastasis Rev        ISSN: 0167-7659            Impact factor:   9.264


  198 in total

1.  Prognostic value of miR-141 downregulation in gastric cancer.

Authors:  Y B Lu; J J Hu; W J Sun; X H Duan; X Chen
Journal:  Genet Mol Res       Date:  2015-12-17

Review 2.  The molecular basis of multidrug resistance in cancer: the early years of P-glycoprotein research.

Authors:  Michael M Gottesman; Victor Ling
Journal:  FEBS Lett       Date:  2005-12-28       Impact factor: 4.124

3.  2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial.

Authors:  Ian Smith; Marion Procter; Richard D Gelber; Sébastien Guillaume; Andrea Feyereislova; Mitch Dowsett; Aron Goldhirsch; Michael Untch; Gabriella Mariani; Jose Baselga; Manfred Kaufmann; David Cameron; Richard Bell; Jonas Bergh; Robert Coleman; Andrew Wardley; Nadia Harbeck; Roberto I Lopez; Peter Mallmann; Karen Gelmon; Nicholas Wilcken; Erik Wist; Pedro Sánchez Rovira; Martine J Piccart-Gebhart
Journal:  Lancet       Date:  2007-01-06       Impact factor: 79.321

Review 4.  RNA interference and its role in cancer therapy.

Authors:  Behzad Mansoori; Siamak Sandoghchian Shotorbani; Behzad Baradaran
Journal:  Adv Pharm Bull       Date:  2014-08-10

5.  Nanostructured lipid carriers as novel drug delivery system for lung cancer gene therapy.

Authors:  Yiqun Han; Ye Li; Peng Zhang; Jiping Sun; Xianzhen Li; Xin Sun; Fansheng Kong
Journal:  Pharm Dev Technol       Date:  2015-01-05       Impact factor: 3.133

6.  Drug resistant breast cancer cells overexpress ETS1 gene.

Authors:  Meltem Demirel Kars; Ozlem Darcansoy Işeri; Ufuk Gündüz
Journal:  Biomed Pharmacother       Date:  2010-02-25       Impact factor: 6.529

7.  Co-delivery of HIF1α siRNA and gemcitabine via biocompatible lipid-polymer hybrid nanoparticles for effective treatment of pancreatic cancer.

Authors:  Xiao Zhao; Feng Li; Yiye Li; Hai Wang; He Ren; Jing Chen; Guangjun Nie; Jihui Hao
Journal:  Biomaterials       Date:  2015-01-15       Impact factor: 12.479

8.  Effect of size and pegylation of liposomes and peptide-based synthetic lipoproteins on tumor targeting.

Authors:  Jie Tang; Rui Kuai; Wenmin Yuan; Lindsey Drake; James J Moon; Anna Schwendeman
Journal:  Nanomedicine       Date:  2017-04-18       Impact factor: 5.307

9.  Breaking up the correlation between efficacy and toxicity for nonviral gene delivery.

Authors:  Miriam Breunig; Uta Lungwitz; Renate Liebl; Achim Goepferich
Journal:  Proc Natl Acad Sci U S A       Date:  2007-08-28       Impact factor: 11.205

10.  A doxorubicin delivery platform using engineered natural membrane vesicle exosomes for targeted tumor therapy.

Authors:  Yanhua Tian; Suping Li; Jian Song; Tianjiao Ji; Motao Zhu; Gregory J Anderson; Jingyan Wei; Guangjun Nie
Journal:  Biomaterials       Date:  2013-12-15       Impact factor: 12.479

View more
  36 in total

Review 1.  A patent review of the ubiquitin ligase system: 2015-2018.

Authors:  Xin Li; Ekinci Elmira; Sagar Rohondia; Jicang Wang; Jinbao Liu; Q Ping Dou
Journal:  Expert Opin Ther Pat       Date:  2018-11-23       Impact factor: 6.674

Review 2.  RNA therapy: Are we using the right molecules?

Authors:  Ai-Ming Yu; Chao Jian; Allan H Yu; Mei-Juan Tu
Journal:  Pharmacol Ther       Date:  2018-12-04       Impact factor: 12.310

Review 3.  Recent advances in targeted delivery of non-coding RNA-based therapeutics for atherosclerosis.

Authors:  Xiaoxin Li; Hongzhao Qi; Weigang Cui; Zhibin Wang; Xiuxiu Fu; Tianxiang Li; Huibo Ma; Yanyan Yang; Tao Yu
Journal:  Mol Ther       Date:  2022-08-01       Impact factor: 12.910

4.  Critical Evaluation of Different Lysosomal Labeling Methods Used to Analyze RNA Nanocarrier Trafficking in Cells.

Authors:  Shoaib Iqbal; Benjamin Luo; Jilian R Melamed; Emily S Day
Journal:  Bioconjug Chem       Date:  2021-09-20       Impact factor: 6.069

5.  Stealth oxime ether lipid vesicles promote delivery of functional DsiRNA in human lung cancer A549 tumor bearing mouse xenografts.

Authors:  Anu Puri; Faisal Ibrahim; André O'Reilly Beringhs; Camryn Isemann; Paul Zakrevsky; Abigail Whittenburg; Derek Hargrove; Tapan Kanai; Rebecca S Dillard; Natalia de Val; Michael H Nantz; Xiuling Lu; Bruce A Shapiro
Journal:  Nanomedicine       Date:  2022-06-04       Impact factor: 6.096

Review 6.  Improving the therapeutic efficiency of noncoding RNAs in cancers using targeted drug delivery systems.

Authors:  Rami Alzhrani; Hashem O Alsaab; Alex Petrovici; Ketki Bhise; Kushal Vanamala; Samaresh Sau; Matthew J Krinock; Arun K Iyer
Journal:  Drug Discov Today       Date:  2019-11-20       Impact factor: 7.851

7.  Preliminary preclinical study of Chol-DsiRNA polyplexes formed with PLL[30]-PEG[5K] for the RNAi-based therapy of breast cancer.

Authors:  Zhen Ye; Mai Mohamed Abdelmoaty; Vishakha V Ambardekar; Stephen M Curran; Shetty Ravi Dyavar; Lora L Arnold; Samuel M Cohen; Devendra Kumar; Yazen Alnouti; Don W Coulter; Rakesh K Singh; Joseph A Vetro
Journal:  Nanomedicine       Date:  2021-02-03       Impact factor: 5.307

8.  Optimizing Perioperative Use of Opioids: A Multimodal Approach.

Authors:  Maria F Ramirez; Brinda B Kamdar; Juan P Cata
Journal:  Curr Anesthesiol Rep       Date:  2020-09-07

Review 9.  Preclinical Advances in Theranostics for the Different Molecular Subtypes of Breast Cancer.

Authors:  Hanyi Fang; Alessandra Cavaliere; Ziqi Li; Yiyun Huang; Bernadette Marquez-Nostra
Journal:  Front Pharmacol       Date:  2021-04-27       Impact factor: 5.810

10.  Mechanisms of Drug Resistance and Use of Nanoparticle Delivery to Overcome Resistance in Breast Cancers.

Authors:  Huseyin Beyaz; Hasan Uludag; Doga Kavaz; Nahit Rizaner
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.